# Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

> **NCT01249690** · PHASE4 · UNKNOWN · sponsor: **Second Military Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib,Pirarubicin,Dexamethasone
- **DRUG:** Thalidomide,Pirarubicin,Dexamethasone

## Key facts

- **NCT ID:** NCT01249690
- **Lead sponsor:** Second Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-06
- **Primary completion:** 2012-06
- **Final completion:** 2014-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2010-11-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01249690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01249690, "Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01249690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*